French health technology company Withings unveiled its most ambitious product yet at CES 2026: the Body Scan 2, a smart scale that goes far beyond weight measurement to track over 60 longitudinal biomarkers. Priced at $600 and expected to launch in the second quarter of 2026 pending FDA clearance, the device represents a significant bet that consumers will pay premium prices for preventive health monitoring at home.

Beyond the Bathroom Scale

The Body Scan 2 builds on its 2023 predecessor with several advanced features that blur the line between consumer wellness device and medical diagnostic tool. The marquee capability is hypertension risk detection—using a clinically validated AI model, the scale estimates blood pressure trends based on each scan without requiring a separate cuff.

This approach addresses one of the fundamental challenges in cardiovascular health monitoring: compliance. Most people don't use blood pressure cuffs regularly, even when prescribed by physicians. By integrating blood pressure estimation into a device people already step on daily, Withings aims to catch hypertension risk earlier when intervention is most effective.

"The Body Scan 2 represents our vision of proactive health—catching potential problems before they become serious, right from the bathroom floor."

— Withings product announcement

The 60-Biomarker Suite

Weight and blood pressure estimation are just the beginning. The Body Scan 2 tracks an extensive list of health metrics:

  • Body Composition: Fat mass, muscle mass, water percentage, and bone mass using advanced bioelectrical impedance analysis
  • Cardiovascular Health: Heart age estimation, artery elasticity assessment, and heart pumping efficiency via impedance cardiography
  • Metabolic Function: Glycemic dysregulation patterns that could indicate prediabetes risk
  • Cellular Health: Bioimpedance spectroscopy to assess cellular membrane function
  • Nervous System: Chronic stress indicators through heart rate variability analysis

All of this data synthesizes into a single "Health Trajectory" score representing predicted years of healthy life. While Withings emphasizes that these features provide early warning signs rather than diagnostic conclusions, the comprehensiveness of the monitoring approaches what previously required multiple medical appointments.

Hardware Innovations

The Body Scan 2 introduces meaningful design changes from its predecessor. The color display has moved from the scale's base into a retractable handle, which houses four electrodes. Combined with eight EKG-capable electrodes on the glass surface, the device creates a full-body electrical circuit for measurements Withings claims are more accurate than typical foot-only smart scales.

The six-lead electrocardiogram capability provides medical-grade heart rhythm monitoring, including atrial fibrillation detection—a feature that requires FDA clearance and represents a genuine clinical application beyond wellness tracking.

The Investment Thesis

For investors watching the connected health space, Withings represents an interesting case study in premium positioning. The Body Scan 2's $600 price point places it firmly in luxury territory—basic smart scales sell for under $50, and even feature-rich competitors rarely exceed $200.

Withings is betting that a meaningful segment of health-conscious consumers will pay for comprehensive monitoring and the peace of mind it provides. The company's target demographic likely includes people with family histories of cardiovascular disease, fitness enthusiasts who want granular body composition data, and early adopters willing to pay for cutting-edge health technology.

The competitive landscape includes both consumer electronics giants and healthcare-focused startups. Apple Watch has established a beachhead in continuous health monitoring, while companies like Oura focus on sleep and recovery metrics. The Body Scan 2 occupies a distinct niche: comprehensive biometric analysis tied to a daily ritual most people already have.

Privacy and Certification

Health data sensitivity presents both opportunities and challenges for connected health devices. Withings emphasizes that the Body Scan 2 meets GDPR and HIPAA requirements and carries ISO 27001 and 27701 certifications—important assurances for privacy-conscious consumers.

The FDA clearance process for the hypertension risk and atrial fibrillation features adds credibility but also timeline uncertainty. Withings has experience navigating FDA approval, having secured clearance for previous ECG features, but the hypertension detection capability represents new territory for the agency.

The Broader Trend

The Body Scan 2 arrives amid growing interest in preventive health and longevity optimization. The success of companies like Whoop, the popularity of continuous glucose monitors among non-diabetics, and the emergence of "longevity clinics" all point to consumer willingness to invest in health monitoring and optimization.

Whether this translates into mainstream adoption of $600 bathroom scales remains to be seen. But for the wellness-focused affluent consumer, the Body Scan 2 offers a compelling value proposition: daily health insights that previously required medical visits, delivered from the bathroom floor every morning.

Availability is expected in Q2 2026, giving Withings several months to complete the FDA clearance process and build distribution. For investors and consumers alike, the Body Scan 2 represents an early indicator of how far the smart health device category can stretch into premium territory.